Sermorelin vs CJC-1295: GHRH Analogs Compared

Sermorelin and CJC-1295 are both synthetic analogs of growth hormone releasing hormone (GHRH) that stimulate the pituitary gland to produce and release growth hormone. Sermorelin is the first 29 amino acids of natural GHRH (GRF 1-29) and was the first GHRH analog developed for research. CJC-1295 (without DAC) is a modified version of GRF 1-29 with four amino acid substitutions that protect it from enzymatic degradation, resulting in greater potency and a slightly longer half-life in test subjects. For research purposes only.

Structure: Sermorelin = GRF(1-29) native sequence | CJC-1295 = Modified GRF(1-29) with 4 substitutions Half-life: Sermorelin = ~10-20 minutes | CJC-1295 No DAC = ~30 minutes Potency: Sermorelin = Moderate | CJC-1295 = Higher (enzymatic resistance) Dose range: Sermorelin = 100-300 mcg daily | CJC-1295 = 100-300 mcg daily Vial sizes: Sermorelin = 10mg | CJC-1295 = 5mg, 10mg Stacking with secretagogues: Both = Standard practice Research history: Sermorelin = Longer (1990s) | CJC-1295 = More recent Enzymatic degradation: Sermorelin = Susceptible | CJC-1295 = Resistant GH pulse amplitude: Sermorelin = Moderate | CJC-1295 = Higher

Choose sermorelin when: The protocol requires the most physiologically similar GHRH analog (native sequence), historical comparability with older research is important, or a gentler GH stimulation is preferred in test subjects. Choose CJC-1295 (No DAC) when: Greater potency per microgram is desired, enzymatic resistance is important for consistent results, or the protocol requires the strongest pulsatile GHRH signal for stacking with secretagogues in test subjects. CJC-1295 No DAC has largely superseded sermorelin in modern research protocols due to its superior enzymatic stability and potency. However, sermorelin retains value for protocols requiring the closest match to endogenous GHRH signalling. For research purposes only.